Abstract 591P
Background
KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell lung cancer (nsqNSCLC). Tyrosine kinase inhibitors (TKIs)- sotorasib and adagrasib are approved for use in patients(pts) with KRASG12C variant. A novel TKIs- active in other KRAS variants are in development. Therefore all potentially targetable KRAS variants should be routinely tested in advanced NSCLC. The next generation sequencing (NGS) is recommended for simultaneous testing of potentially actionable biomarkers.
Methods
The study was performed as part of routine genetic diagnosis of pts with nsqNSCLC within a single institution between Jan.2019-May.2023. The material for the study consisted of tissue and cytologic samples containing no less than 20% of the tumor cells. The NGS method was used to assess the mutation status of the KRAS gene. Samples were sequenced using the FusionPlex CTL ArcherDx assay on a MiniSeq instrument (Illumina).
Results
In a group of 1468 real-world patients (pts) with advanced nsqNSCLC tested with NGS KRAS prevalence was 32,3% (474 pts). KRASG12C variant was observed in 229 pts representing 15,6% pts with nsqNSCLC and 48,3% of all KRAS mutant pts. In KRAS mutant group in cytological and tissue specimen the most common variants occurred accordingly in: Gly12Cys (50%, 48%), Gly12Asp (20%, 15%), Gly12Ala (9%, 8%), Gly12Val (14%, 15%), other variants less than 5% each (table). KRAS and other mutation coexisted in 7% (34 of 474) pts. The incidence of molecular KRAS variants diagnosed with NGS were comparable between the cytological and tissue specimen. Table: 591P
Variant | All KRAS pts N=474 (100%) | Cytology N=88 (100%) | Tissue N=386 (100%) | |||
N | % | N | % | N | % | |
Gln61His | 20 | 4,22% | 2 | 2,27% | 18 | 4,7% |
Gly12Ala | 40 | 8,44% | 8 | 9,09% | 32 | 8,3% |
Gly12Asp | 75 | 15,82% | 18 | 20,45% | 57 | 14,8% |
Gly12Cys | 229 | 48,31% | 44 | 50,00% | 185 | 47,9% |
Gly12Val | 71 | 14,98% | 12 | 13,64% | 59 | 15,3% |
Gly12Ser | 9 | 1,90% | 1 | 1,14% | 8 | 2,1% |
Gln61Leu | 6 | 1,27% | 1 | 1,14% | 5 | 1,3% |
exon2 | 8 | 1,69% | 1 | 1,14% | 7 | 1,8% |
Gln61Lys | 7 | 1,48% | 1 | 1,14% | 6 | 1,6% |
Gly12Phe | 4 | 0,84% | 0 | 0,00% | 4 | 1,0% |
Gly12Arg | 2 | 0,42% | 0 | 0,00% | 2 | 0,5% |
Lys117Asn | 1 | 0,21% | 0 | 0,00% | 1 | 0,3% |
Gln61Arg | 2 | 0,42% | 0 | 0,00% | 2 | 0,5% |
Conclusions
The NGS is feasible for diagnosis of the KRAS mutations in real-world practice. The utility of both cytological and tissue testing is high for NGS profiling with comparable prevalence of the most frequent KRAS variants.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions
Presenter: Shanavas Palliyal
Session: Poster Display
Resources:
Abstract
383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma
Presenter: Ni Putu Pusvita Dewi
Session: Poster Display
Resources:
Abstract
384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan
Presenter: Wei-Chen Lu
Session: Poster Display
Resources:
Abstract
385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer
Presenter: Hyun Jin Bang
Session: Poster Display
Resources:
Abstract
386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal
Presenter: Huawei Tuo
Session: Poster Display
Resources:
Abstract
387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
388P - Clinicopathological correlation of P53 expression in oral cancers
Presenter: Venkata Madhavi Bellala
Session: Poster Display
Resources:
Abstract
389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab
Presenter: James A. Bonner
Session: Poster Display
Resources:
Abstract
390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan
Presenter: Akhrorbek Yusupbekov
Session: Poster Display
Resources:
Abstract
391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients
Presenter: FathAlrahman Ibrahim
Session: Poster Display
Resources:
Abstract